Dijon

• A Phase 3 Study of Obexelimab in Patients with IgG4-Related Disease Recruiting
  2022-500718-24-00 5 2023-06-09 IgG4-Related Disease
• Phase 3, Open-label Study of ARV-471 (PF-07850327) vs Fulvestrant in Participants With ER(+)/ HER2(-) Advanced Breast Cancer (VERITAC-2) Recruiting
  2022-500544-38-00 5 2023-06-05 Advanced Breast Cancer
• A Study of E7386 in Combination With Other Anticancer Drug(s) in Subjects With Solid Tumors Recruiting
  2023-510275-64-00 9 2023-05-31 Hepatocellular carcinoma, colorectal cancer, endometrial cancer, or ot
• A Phase 1 first in human study evaluating safety, pharmacokinetics and efficacy of ABBV-400 as monotherapy and in combination with bevacizum … Recruiting
  2023-509335-60-00 1 2023-02-23 Advanced solid tumors including (but not limited to), non-small cell l
• This study is to find out the safety and effectiveness of Epcoritamab together with R-CHOP (rituximab, cyclophosphamide, doxorubicin HCL, vi … Recruiting
  2023-505277-32-00 5 2023-01-26 Diffuse Large B-Cell Lymphoma (DLBCL)
• Efficacy and Safety of Tozorakimab in Patients Hospitalised for Viral Lung Infection Requiring Supplemental Oxygen (TILIA). Recruiting
  2023-507031-38-00 5 2023-01-09 Severe viral lung infections
• Rituximab in patients with ST-elevation myocardial infarction. A phase 2 placebo-controlled randomized clinical trial. Recruiting
  2022-501893-21-00 4 2022-05-03 Acute myocardial infarction
• Randomised phase III trial of ADT +/- darolutamide in frail men with castration-naïve de novo metastatic prostate cancer Recruiting
  2022-502425-18-00 5 2022-04-19 Adenocarcinoma of the prostate
• NEoadjuvant chemoradiotherapy for Esophageal squamous cell carcinoma versus Definitive chemoradiotherapy with salvage Surgery as needed (The … Recruiting
  2022-500966-82-00 5 2020-03-11 Resectable locally advanced squamous cell carcinoma (SCC) of the esoph
• A multi-center phase III randomized study comparing continuous versus fixed duration therapy with Daratumumab, Lenalidomide, and Dexamethaso … Recruiting
  2024-511855-16-00 5 2019-07-25 Onco-hematology
• STARS (Secukinumab in TAkayasu ARteritiS) Recruiting
  2024-516215-24-00 4 2026-07-01 TAkayasu ARteritiS
• Study of Taxane-Platinum followed by a maintenance with avelumab and cetuximab in First Line Recurrent or Metastatic Squamous Cell Carcinoma … Recruiting
  2023-510559-41-00 4 2026-06-15 Recurrent or Metastatic Squamous Cell Carcinoma of the Head and Neck
• DESIRE MS: A prospective randomized non-inferiority trial comparing anti-CD20 maintenance versus De-Escalation Strategy In Relapsing-Remitti … Recruiting
  2024-513292-40-00 5 2026-06-15 Multiple sclerosis
• A trial to learn how safe durvalumab with chemotherapy is and how well it works in adults with muscle-invasive bladder cancer Recruiting
  2024-519246-75-01 4 2026-06-15 Patients With Muscle-Invasive Bladder Cancer
• Duration of Dual Anti-Platelet Therapy in Chronic Limb Threatening Ischemia after Distal Revascularization: a randomized, double-blind trial Recruiting
  2025-524297-42-00 5 2026-06-12 CLTI defined as Rutherford category 4 or 5
• Rifampin-free regimen versus rifampin-containing regimen in the treatment of staphylococcal prosthetic valve endocarditis: a multicenter ran … Recruiting
  2024-518018-22-00 5 2026-06-11 staphylococcal endocarditis
• OPTIMAL CARE WITH GUSELKUMAB IN CROHN’S DISEASE Recruiting
  2025-524573-16-00 6 2026-06-11 Crohn's disease
• A Study of S241656 in Patients With KRAS, BRAF and Other Selected RAS/MAPK Mutation-Positive Malignancies Recruiting
  2025-523474-16-00 7 2026-06-09 Malignancies with Documented KRAS, BRAF and Other Selected RAS/MAPK Mu
• A clinical trial to learn more about the effects of FWY003 in people with geographic atrophy associated with age-related macular degeneratio … Recruiting
  2025-523704-77-00 4 2026-06-04 Geographic atrophy secondary to age-related macular degeneration
• PROlonged Corticosteroid treatment or N-ACetylcysteine for severe alcoholic hepatitis (PROCORNAC) Recruiting
  2025-522109-39-00 5 2026-05-22 Alcoholic hepatitis
• DIROXIMEL FUMARATE TO REDUCE PERIHAEMATOMAL OEDEMA IN INTRACEREBRAL HAEMORRHAGE: A DOUBLE BLIND RANDOMIZED CLINICAL TRIAL Recruiting
  2025-522687-33-00 5 2026-05-19 Stroke
• A clinical study of belzutifan and zanzalintinib in people with advanced kidney cancer (MK-6482-034) Recruiting
  2024-516993-31-00 5 2026-05-11 Renal Cell Carcinoma
• A clinical study to evaluate the effects of RO7795068 in participants with obesity or overweight without type 2 diabetes. Recruiting
  2025-523104-71-00 5 2026-05-08 Obesity or Overweight Without Type 2 Diabetes
• PRODIGE 88-CIRCULATE PAC: Phase III multicentric, open-label, randomized study to investigate the efficacy of chemotherapy in patients with … Recruiting
  2023-505046-26-00 5 2026-05-07 Colon carcinoma

Showing 145–168 of 825 trials